JPS611666A - Novel 2(1h)-quinolone derivative - Google Patents

Novel 2(1h)-quinolone derivative

Info

Publication number
JPS611666A
JPS611666A JP12308384A JP12308384A JPS611666A JP S611666 A JPS611666 A JP S611666A JP 12308384 A JP12308384 A JP 12308384A JP 12308384 A JP12308384 A JP 12308384A JP S611666 A JPS611666 A JP S611666A
Authority
JP
Japan
Prior art keywords
extract
alcohol
lower alcohol
compound
under reduced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP12308384A
Other languages
Japanese (ja)
Other versions
JPH0458467B2 (en
Inventor
Juji Okayasu
重次 岡安
Katsuhiro Hamada
浜田 勝宏
Hisashi Shimizu
久 清水
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OKAYASU SHOTEN KK
Original Assignee
OKAYASU SHOTEN KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OKAYASU SHOTEN KK filed Critical OKAYASU SHOTEN KK
Priority to JP12308384A priority Critical patent/JPS611666A/en
Publication of JPS611666A publication Critical patent/JPS611666A/en
Publication of JPH0458467B2 publication Critical patent/JPH0458467B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Quinoline Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

NEW MATERIAL:3,6-Dihydroxy-3-methoxycarbonyl-3,4-dihydro-2(1H)-quinolone of the formula and its salt. USE:Immune regulator, antiallergic and anti-inflammatory analgesic. PREPARATION:Dried rice bran is dipped in a lower alcohol to obtain a primary extract, when needed, the extract is combined with a lower alcohol, further mixed with a hydrophobic solvent such as n-hexane and water. After thoroughly stirring, the mixture is separated into the aqueous phase and the solvent phase and the aqueous phase which contains alcohol, but no lipids is collected, concentrated under reduced pressure to dryness, then a lower alcohol is added to the residue to obtain the secondary extract containing substances soluble in alcohol. The extract is concentrated under reduced pressure and mixed with a mixed solvent of a lower alcohol and chloroform. Then, the supernatant is subjected to column chromatography or thin-film chromatography to give the compound of formula I.

Description

【発明の詳細な説明】 産業上の利用分野 本発明は免疫調節作用、抗アレルギー作用及び消炎鎮痛
作用を有する新規2(1・H)−キノロン誘導体に関し
、さらに詳しくは3,6−シヒドロキシー3−メトキシ
カルぜニル−3,4−ジヒドロ−2(IH)−キノロン
(以下、化合物〔1〕と称する)及びその塩化係る。
DETAILED DESCRIPTION OF THE INVENTION Field of Industrial Application The present invention relates to novel 2(1·H)-quinolone derivatives having immunomodulatory, antiallergic, and antiinflammatory and analgesic effects, and more specifically to 3,6-hydroxy-3-quinolone derivatives. This invention relates to methoxycarzenyl-3,4-dihydro-2(IH)-quinolone (hereinafter referred to as compound [1]) and its salification.

発明の目的 本発明の目的は免疫調節剤、抗アレルギー剤バび消炎鎮
痛剤の有−成分となり得る化i物(13とその塩を提供
すること化ある。
OBJECTS OF THE INVENTION The object of the present invention is to provide compound (13) and its salts which can be used as an ingredient of immunomodulators, anti-allergy agents, anti-inflammatory analgesics.

1.′ 本発明あ化合物CI〕t−1上記の化学構造式を有し、
□その3位及び/又は6位のヒドロキシル基に、医薬上
許容される強塩基性化合物、例えば水酸化ナトリウム、
水酸化カリウム、水酸化物(1)の塩を容島に得ること
ができる。本発明の化合物CI)及びその塩は、免疫調
節作用、抗ア、;ヤ・ヤー作え及び消炎鎮痛作用□有6
、従って、免疫調節剤、抗アレルギー剤及び消炎鎮痛剤
の薬効成分として極めて有用である。
1. 'Compound CI]t-1 of the present invention has the above chemical structural formula,
□ At the hydroxyl group at the 3rd and/or 6th position, a pharmaceutically acceptable strong basic compound such as sodium hydroxide,
Potassium hydroxide, a salt of hydroxide (1), can be obtained from Yoshima. The compound CI) of the present invention and its salts have immunomodulatory, anti-inflammatory, anti-inflammatory and analgesic effects.
Therefore, it is extremely useful as a medicinal ingredient for immunomodulators, anti-allergy agents, and anti-inflammatory analgesics.

尚、本発明の化合物〔I〕は、そのラセミ体及び光学異
性体をも包含する。
In addition, the compound [I] of the present invention also includes its racemate and optical isomer.

本発明の化合物CI)は、例えば米糠より容易に単離す
ることができる。単離手段としては、溶媒抽出、カラム
クロマトグラフィー、薄層クロマトグラフィーなどの公
知の分離方法が採用される。米糠から化合物CI)を単
離する方法の一例を述べれば、望プしくけ乾燥状態にあ
る米糠を、メタノール、エタノール、イソプロパツール
などの低級アルコールに常温乃至50″Cで浸漬してア
ルコール可溶分を米糠から抽出し、第1次抽出液を得る
。この第1次抽出液に必要ならば低級アルコールを加え
、さらに疎水性溶媒(例えばn−ヘキサン)と水を加え
て充分に混合し、混合液を静置するか遠心分離にかける
ことによって分層させ、低級アルコールを含有し、脂質
を含まない水溶液を分取する。次にこの水溶液を減圧濃
縮又は減圧乾固した後、改めて低級アルコールを加えて
アルコール可溶物をこれに溶解させ、アルコール不溶物
(糖質)′tl−アルコール溶液から除去して第2次抽
出液を得る。
Compound CI) of the invention can be easily isolated from rice bran, for example. As the isolation means, known separation methods such as solvent extraction, column chromatography, and thin layer chromatography are employed. An example of a method for isolating compound CI) from rice bran is to soak rice bran in a dry state in a lower alcohol such as methanol, ethanol, isopropanol, etc. at room temperature to 50"C. The soluble matter is extracted from the rice bran to obtain a first extract. If necessary, lower alcohol is added to this first extract, and a hydrophobic solvent (e.g. n-hexane) and water are added and mixed thoroughly. The mixture is allowed to stand still or centrifuged to separate the layers, and an aqueous solution containing lower alcohols and no lipids is collected.Next, this aqueous solution is concentrated under reduced pressure or dried under reduced pressure, and then the lower alcohols are separated again. Alcohol is added to dissolve alcohol-soluble substances therein, and alcohol-insoluble substances (carbohydrates) are removed from the 'tl-alcohol solution to obtain a second extract.

こうして得た第2次抽出液を望ましくは減圧濃縮した後
、これに低級アルコールとクロロホルムの混合液を添加
して混合し、生成するタール様物質を沈降させて上澄液
を採取する。次いでこの上澄液を減圧乾固させて得られ
る物質を低級アルコールに溶解し、そのアルコール溶液
をカラムクロマトグラフィー又は薄層クロマトグラフィ
ーにかけることにより、目的物たる化合物CI)を単離
することができる。
After the secondary extract thus obtained is preferably concentrated under reduced pressure, a mixture of lower alcohol and chloroform is added and mixed, the resulting tar-like substance is precipitated, and the supernatant is collected. Next, the substance obtained by drying this supernatant under reduced pressure is dissolved in a lower alcohol, and the alcohol solution is subjected to column chromatography or thin layer chromatography to isolate the target compound, compound CI). can.

カラムクロマトグラフィーの担体には、例えばシリカゲ
ル、活性アルミナ、硝酸銀シリカゲルなどが使用可能で
あり、溶離剤としては、例、tばn−ベキサン、kンゼ
ン、ジエチルエーテル、クロロホルム、酢酸エチル、ア
セトン、メタノール、エタノール及びこれらの混合物−
が使用可能である。
For example, silica gel, activated alumina, silver nitrate silica gel, etc. can be used as a carrier for column chromatography, and examples of eluents include tban-bexane, konzene, diethyl ether, chloroform, ethyl acetate, acetone, and methanol. , ethanol and mixtures thereof-
is available.

以下、実施例を掲げて本発明をさらに説明する。The present invention will be further explained below with reference to Examples.

実施例 乾燥した米糠10kf1i−40℃に加温したメタノー
ル5olに1時間浸漬して抽出を行ない、得られた第1
次抽出液を減圧下に511で濃縮する。この濃縮液にn
−ヘキサン10/及び水101を加えて40℃で振りま
ぜた後、これを静置すると、メタノールを含む水性溶液
が下層に分離されるので、これを分液して水性溶液を得
る。次にこの水性溶液を減圧下に蒸発乾固し、乾固物に
純メタノール51を加えて糖質を析出させ、析出物を濾
過で除去することにより、メタノール溶液(第2次抽出
液)を得る。このメタノール溶液を蒸発乾固した後、メ
タノール・クロロホルム混合溶媒(容積比2:8)51
を加え、生成するタール様物質を沈降させ、上澄液を分
離する。次いで、この上澄液を蒸発乾固してから改めて
これにメタノールを加え、メタノール溶液を調製する。
Example 10 kf1i of dried rice bran was extracted by immersing it in 5 ol of methanol heated to 40°C for 1 hour.
The extract is then concentrated at 511 under reduced pressure. This concentrate contains n
- After adding 10 parts of hexane and 10 parts of water and shaking at 40°C, when this is left to stand, an aqueous solution containing methanol is separated into a lower layer, and this is separated to obtain an aqueous solution. Next, this aqueous solution is evaporated to dryness under reduced pressure, pure methanol 51 is added to the dried product to precipitate carbohydrates, and the precipitate is removed by filtration to obtain a methanol solution (secondary extract). obtain. After evaporating this methanol solution to dryness, methanol/chloroform mixed solvent (volume ratio 2:8) 51
is added to precipitate the resulting tar-like substance, and the supernatant liquid is separated. Next, this supernatant liquid is evaporated to dryness, and then methanol is added thereto again to prepare a methanol solution.

他方、メルク社製のKiesel薩el 60Gで厚さ
Q、 5 mmの薄層を作り、120℃で1時間これを
活性化させる。この薄層に、先に調製したメタノール溶
液を線状にスポットし、メタメール・クロロホルム混合
溶媒(容積比1:9)で10 cm展開させ、Rf値−
〇、26の部分を集めてメタノールで抽出する。しかる
後、このメタノール抽出液からメタノールを留去するこ
とにより、3,6−シヒドロキシー3−メトキシカルI
ニルー3,4−ジヒドロ−2(IH)−キノロン500
mgを得た。
On the other hand, a thin layer with a thickness Q of 5 mm is made with Kiesel Satsuel 60G manufactured by Merck and activated at 120° C. for 1 hour. On this thin layer, the previously prepared methanol solution was spotted linearly, and developed for 10 cm with a mixed solvent of metamer and chloroform (volume ratio 1:9) to determine the Rf value -
Collect parts ○ and 26 and extract with methanol. Thereafter, by distilling off methanol from this methanol extract, 3,6-cyhydroxy-3-methoxycarboxylic acid
Nilu-3,4-dihydro-2(IH)-quinolone 500
mg was obtained.

当該化合物の物理的及び化学的性状は下記の通りである
The physical and chemical properties of the compound are as follows.

外 観 ;黄褐色結晶性粉末 融  点  : 67〜68°C 比旋光度;〔α]D−−3.8°(C1,OMeOH)
溶解性:水及び低級アルコールに易溶。酢酸エチル、ク
ロロホルム、ベンゼ ンにS溶。
Appearance: Yellow-brown crystalline powder Melting point: 67-68°C Specific rotation: [α]D--3.8° (C1, OMeOH)
Solubility: Easily soluble in water and lower alcohols. S dissolved in ethyl acetate, chloroform, and benzene.

味   :水溶液は苦味を呈する。Taste: The aqueous solution has a bitter taste.

元素分析値(C,、H,、N O,として)紫外吸収 核磁気共鳴吸収←第1図及び第2図参照)’HNMR(
CD5OD 、 400BJ)Is )へWLd 2.
97 (IH,d、 J−15,4)−3,03(IH
,d、 J−15,4)−’ 3.49 (3H,8) 、、、= 6.67(IH,dd、 Jm 8.3.2
.3)= 6.70(IH,dd、 J == s、a
 、 o、e )、= 6.84(IH,dd、 Jm
2.3. 0.6)(CD、ODのシグナルを3.30
 ppmとした時)”CNMR(DM80−d、 、 
tlMHz )1’、、、y1=−41,5、50,7
、72,9、109,6。
Elemental analysis values (as C,, H,, NO) Ultraviolet absorption Nuclear magnetic resonance absorption (See Figures 1 and 2) 'HNMR
CD5OD, 400BJ)Is) to WLd 2.
97 (IH,d, J-15,4)-3,03(IH
,d, J-15,4)-' 3.49 (3H,8) ,,,=6.67(IH,dd, Jm 8.3.2
.. 3) = 6.70 (IH, dd, J == s, a
, o, e ), = 6.84 (IH, dd, Jm
2.3. 0.6) (CD, OD signal 3.30
ppm)”CNMR (DM80-d, ,
tlMHz)1',,y1=-41,5,50,7
, 72,9, 109,6.

112.1  、 115.0  、 131.7  
、 133.8  。
112.1, 115.0, 131.7
, 133.8.

152.3  、 168.8  、 177.4(D
M90−d、を39.5’として)質量ス(クトル(第
3図参照) 即’Z  237(M”、 C,、Hl、NO,)。
152.3, 168.8, 177.4 (D
M90-d, as 39.5') mass (see Figure 3) Z 237 (M'', C,, Hl, NO,).

219(M−)1.(1)。219(M-)1. (1).

185 、177(M−C,H40,) 。185, 177 (MC, H40,).

164 、135(M−C,H,O,)赤外スペクトル
(第4図参照・・・・・・KBr錠剤法)
164, 135 (MC, H, O,) infrared spectrum (see Figure 4...KBr tablet method)

【図面の簡単な説明】[Brief explanation of drawings]

1141図は実施例で得た本発明の化合物〔l〕の1H
核磁気共鳴スペクトルを、第2図は同じく化合物(1)
の130核磁気共鳴スペクトル金示す。 第3図は実施例で得た本発明の化合物(1)のマススペ
クトルを、第4図は同じく化合資(I)の赤外スペクト
ルを示す。 完 1図
Figure 1141 shows 1H of the compound [l] of the present invention obtained in Example.
Figure 2 shows the nuclear magnetic resonance spectrum of compound (1).
130 nuclear magnetic resonance spectrum of gold. FIG. 3 shows the mass spectrum of the compound (1) of the present invention obtained in the example, and FIG. 4 similarly shows the infrared spectrum of the compound (I). Complete 1 diagram

Claims (1)

【特許請求の範囲】 1、式 ▲数式、化学式、表等があります▼〔 I 〕 で示される3,6−ジヒドロキシ−3−メトキシカルボ
ニル−3,4−ジヒドロ−2(1H)−キノロン又はそ
の塩。
[Claims] 1. 3,6-dihydroxy-3-methoxycarbonyl-3,4-dihydro-2(1H)-quinolone or its salt.
JP12308384A 1984-06-15 1984-06-15 Novel 2(1h)-quinolone derivative Granted JPS611666A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP12308384A JPS611666A (en) 1984-06-15 1984-06-15 Novel 2(1h)-quinolone derivative

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP12308384A JPS611666A (en) 1984-06-15 1984-06-15 Novel 2(1h)-quinolone derivative

Publications (2)

Publication Number Publication Date
JPS611666A true JPS611666A (en) 1986-01-07
JPH0458467B2 JPH0458467B2 (en) 1992-09-17

Family

ID=14851772

Family Applications (1)

Application Number Title Priority Date Filing Date
JP12308384A Granted JPS611666A (en) 1984-06-15 1984-06-15 Novel 2(1h)-quinolone derivative

Country Status (1)

Country Link
JP (1) JPS611666A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10973702B2 (en) 2015-08-26 2021-04-13 The Procter & Gamble Company Absorbent articles having three dimensional substrates and indicia
US11033440B2 (en) 2014-03-06 2021-06-15 The Procter & Gamble Company Three-dimensional substrates
TWI817867B (en) * 2022-12-15 2023-10-01 大江生醫股份有限公司 Use of 1,2,3,4-tetrahydroquinoline derivatives for improving atherosclerosis

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11033440B2 (en) 2014-03-06 2021-06-15 The Procter & Gamble Company Three-dimensional substrates
US10973702B2 (en) 2015-08-26 2021-04-13 The Procter & Gamble Company Absorbent articles having three dimensional substrates and indicia
TWI817867B (en) * 2022-12-15 2023-10-01 大江生醫股份有限公司 Use of 1,2,3,4-tetrahydroquinoline derivatives for improving atherosclerosis

Also Published As

Publication number Publication date
JPH0458467B2 (en) 1992-09-17

Similar Documents

Publication Publication Date Title
JPS611666A (en) Novel 2(1h)-quinolone derivative
JP2732259B2 (en) New aconitine compounds and analgesic / anti-inflammatory agents
JPH0533955B2 (en)
CN104086559B (en) A kind of crystal formation of diterpene-kind compound
JPH085862B2 (en) Novel aconitine compounds and analgesic / anti-inflammatory agents containing them as active ingredients
HU180710B (en) Equipment for the isolation by extraction of natural terpenes active against psoriasis from leaves and rhizomes of fern and for preparing pharmaceutical compositions from the extract
EP0541780B1 (en) Antineoplastic chemotherapeutic of plant origin, having high selectivity and greatly reduced toxicity, and process for the preparation thereof
CN104140391A (en) Method for separating and purifying highly pure Euphorbia factor from moleplant seed
JP5675034B2 (en) Neutral lipid absorption inhibitor and saponin compound obtained from daisy and use thereof
Hertelendy et al. Isolation of crystalline 16-epiestriol from hen urine
AU2549892A (en) Antineoplastic drug of plant extraction and process for the preparation thereof
JPS58150584A (en) Kuwanon compound
JP3256746B2 (en) Composition for suppressing cell fibrosis and method for preparing loquat nucleus extract
CN110655483A (en) Alkaloid compound and preparation method and application thereof
JP2001316398A (en) Antiallergic agent
JP2674758B2 (en) Method for isolating liquiritin
JPH021824B2 (en)
JPH035424A (en) Anti-ulcer agent containing flavonoids as active ingredient
JPS6259119B2 (en)
JPS62108858A (en) Trans-n-(2-hydroxyethyl)-3-methylthiopropenamide
Abramovitch et al. Some neutral and acidic extractives from Ceanothus americanus L.
JPS5811960B2 (en) Cyclobranol succinic acid ester alkali metal salt
JPH0665224A (en) Lignan derivative
JPH0378381B2 (en)
JPH0226614B2 (en)

Legal Events

Date Code Title Description
LAPS Cancellation because of no payment of annual fees